Comment on

• Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

  Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A. Kanerva A, et al. Clin Cancer Res. 2013 May 15;19(10):2734-44. doi: 10.1158/1078-0432.CCR-12-2546. Epub 2013 Mar 14. Clin Cancer Res. 2013. PMID: 23493351 Clinical Trial.
• Oncolytic virotherapy needs trials, not access programs.

  Harrington KJ. Harrington KJ. Clin Cancer Res. 2013 May 15;19(10):2595-7. doi: 10.1158/1078-0432.CCR-13-0571. Epub 2013 Apr 2. Clin Cancer Res. 2013. PMID: 23549877